ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

ClinicalTrials.gov ID: NCT02573233

Public ClinicalTrials.gov record NCT02573233. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Exploratory, Double-blind, Placebo-controlled Study of the Effects of Dupilumab on Airway Inflammation of Adults With Persistent Asthma

Study identification

NCT ID
NCT02573233
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Sanofi
Industry
Enrollment
42 participants

Conditions and interventions

Conditions

Interventions

  • Dupilumab SAR231893/REGN668 Drug
  • Placebo Drug
  • budesonide and formoterol Drug
  • fluticasone propionate and salmeterol Drug
  • mometasone furoate and formoterol Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 26, 2016
Primary completion
Jan 2, 2018
Completion
Jan 2, 2018
Last update posted
Apr 3, 2022

2016 – 2018

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
Investigational Site Number 840402 Tucson Arizona 85724
Investigational Site Number 840403 Denver Colorado 80206
Investigational Site Number 840401 Boston Massachusetts 02115
Investigational Site Number 840002 St Louis Missouri 63110
Investigational Site Number 840404 Winston-Salem North Carolina 27157-1071
Investigational Site Number 840028 Pittsburgh Pennsylvania 15213

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02573233, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 3, 2022 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02573233 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →